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Abstract
OBJECTIVE: To document the therapeutic effects
of Feiwei granules (FGs) for idiopathic pulmonary fi-
brosis (IPF).
METHODS: One hundred cases with IPF were ran-
domized into the treatment group (80) and control
group (20). Both groups were given basic treat-
ment with prednisone. The treatment group was
given FGs, and the control group was given Jinshui-
bao capsules (JCs). Treatment lasted for 6 months.
The Medical Research Council Dyspnea Scale
(MRCDS), the Saint George's Hospital Respiratory
Questionnaire (SGHRQ), pulmonary function, the
Traditional Chinese Medicine Syndrome Score (TC-
MSS), 6-min walking test (6MWT) and blood gas
analyses were recorded before the study as well as
3 months and 6 months after treatment.
RESULTS: FGs showed greater efficacy than the
control in certain parameters between before the
study and 6 months, and between 3 months and 6
months, in the MRCDS, some indicators in the
SGHRQ, and the TCMSS. There were no significant
differences between the treatment group and con-
trol group in the remainder of the indices evaluat-
ed. In the treatment group, there were significant
differences in before and after treatment in the
MRCDS, SGHRQ, TCMSS and 6MWT.
CONCLUSION: FGs were similar to JCs for IPF treat-
ment.
Key words: Idiopathic pulmonary fibrosis; Dys-
pnea; Surveys and questionnaires; 6-min walking
test; Feiwei granules; Jinshuibao capsules; Random-
ized controlled trial
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Pulmonary fibrosis is an interstitial lung disease. Idio-
pathic pulmonary fibrosis (IPF) is a progressive, fibros-
ing, interstitial pneumonia of unknown cause. It is
characterized by diffuse inflammation and structural
disorders in alveoli. The most common feature of IPF
is progressive dyspnea. The disease carries a dismal
prognosis, with an estimated median survival of 2.9
years from the time of diagnosis. Five-year survival for
IPF is < 50%.1
Specific therapeutic options for IPF are lacking. Gluco-
corticoids, immunosuppressive agents, cytotoxic drugs
or anti-fibrosis drugs are used commonly, but treat-
ment effects are limited and data from randomized con-
trolled trials scarce.2
Symptoms of pulmonary interstitial fibrosis are mainly
dry cough, dyspnea, and wheezing (particularly upon
exertion). According to the definition described in The
Synopsis of the Golden Chamber, "consumptive lung
disease" is related to pulmonary interstitial fibrosis.3
Previously we demonstrated within Traditional Chi-
nese Medicine (TCM) theory that lung-kidney defi-
ciency and Qi deficiency with blood stasis are the most
common syndromes. Feiwei granules (FGs) are a TCM
prescription. FGs are beneficial to the lungs and kid-
neys, enrich Qi, and activate blood.4 Previously, when
treating 32 IPF patients, we showed that FGs im-
proved symptoms in 75% of cases.5Liu et al 6 found that
the lung function and quality of life (QoL) of IPF pa-
tients were improved significantly after FG treatment.
We wished to evaluate the efficacy of FGs against IPF.
Data collection included dyspnea scores, QoL scores,
total Traditional Chinese Medicine Syndrome Score
(TCMSS), 6-min walking test (6MWT), lung func-
tion, and blood gas analyses.
METHODS
Design
This was a randomized, controlled, clinical study con-
ducted at three centers in Beijing (China-Japan Friend-
ship Hospital, Dongfang Hospital Affiliated to Beijing
University of Chinese Medicine, Xiyuan Hospital Affil-
iated to China Academy of Chinese Medical Sciences),
one in Tianjin (Second Affiliated Hospital of Tianjin
University of TCM), and one in Shandong (Qingdao
Haici Medical Group).
Ethical approval of the study protocol
The study protocol was approved by the Ethics Com-
mittee of Beijing China-Japan Friendship Hospital,
and adhered to the principles of the Declaration of Hel-
sinki. Written informed consent was obtained from all
participants (or their representatives) before enrollment.
Participants
One hundred patients were enrolled from January
2009 to December 2012.
Inclusion criteria were: (a) IPF patients diagnosed ac-
cording to the criteria set by the Chinese Thoracic Soci-
ety;7 (b) IPF patients diagnosed as having "lung-kidney
deficiency, Qi deficiency with blood stasis" according
to TCM principles;8,9 (c) disease severity of mild-to-
moderate; and (d) patients aged 18-70 years.
Exclusion criteria were patients: (a) suffering from
other primary pulmonary diseases (e.g., bronchial
asthma, chronic obstructive pulmonary disease, bron-
chiectasis, lung cancer); (b) who had used TCM
preparations to regulate and supplement their lungs
and kidneys, or who had taken other immune sys-
tem-boosting drugs in the previous month; (c) using
oral glucocorticoid drugs long-term; (d) who were
pregnant, planning to become pregnant, or lactating;
(e) who were allergic; (f ) who had severe primary dis-
eases of the heart, brain, digestive system, or hemato-
poietic system; (g) who did not have the mental ca-
pacity to cooperate with the researchers; (h) with a
partial pressure of oxygen (PO2) at rest ≤ 50 mmHg;
and (i) who had participated in other clinical studies
in the previous month.
Medications
The treatment group was given FGs (Pharmaceutical
Centre of Beijing China-Japan Friendship Hospital).
Each 8-g bag of FG contained Xiyangshen (Radix Pana-
cis Quinquefolii), Sanqi (Radix Notoginseng), Shan-
zhuyu (Fructus Macrocarpii), Wuweizi (Fructus Schisan-
drae Chinensis), Ziwan (Radix Asteris Tatarici), Maid-
ong (Radix Ophiopogonis Japonici), Baiguo (Semen
Ginkgo), and stir-frying with liquid adjuvant Gancao
(Radix Glycyrrhizae).
The control group was given Jinshuibao capsules (JCs;
Jiminkexin Pharmaceuticals, Jiangxi, China).
The basic-treatment group was given prednisone (Bei-
jing Shuguang Pharmaceuticals, Beijing, China). Pa-
tients were started on 0.5 mg/kg body weight (q.i.d.)
in the first month. In the second month they were giv-
en 0.4 mg/kg (q.i.d.), in the third month they were giv-
en 0.3 mg/kg (q.i.d.), and then they were maintained
on 10 mg/day for the next 9 months.
Randomization
Using the stratified randomization method according
to a predetermined proportion of 4∶1, the 100 IPF pa-
tients were randomized to the treatment group or con-
trol group. The data managers were masked through-
out this study.
Treatment
Patients in the treatment group underwent basic treat-
ment and treatment with FGs (two bags at a time, b.
d.). Those in the control group underwent basic treat-
ment and treatment with JCs (three capsules at a time,
t.d.s.). Pharmacologic treatment lasted for 6 months
from the date of enrollment. During this time, patients
were not permitted to receive other medical interven-
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tions for IPF.
Outcome measures
Data were captured before beginning drug administra-
tion and at 3 months and 6 months. Researchers re-
corded the quantity of drugs accepted, taken and re-
turned, and determined compliance with the medica-
tion regimen.
Endpoints
Efficacy outcomes were the Medical Research Council
Dyspnea Scale (MRCDS), Saint George's Hospital Re-
spiratory Questionnaire (SGHRQ), lung function (vi-
tal capacity (VC), forced expiratory volume in 1 sec-
ond/forced vital capacity (FEV1/FVC), FEV1% , total
lung capacity (TLC), diffusing capacity of the lungs for
carbon monoxide (DLCO), diffusing capacity of the
lungs for carbon monoxide/alveolar volume (DLCO/
Va), total TCMSS, 6MWT and blood gas analyses
(pH, PO2, partial pressure of carbon dioxide (PCO2)
HCO3).
Safety indices
General medical examination, regular blood and urine
tests, electrocardiography [(ECG, liver function (ala-
nine aminotransferase (ALT)], renal function (blood
urea nitrogen (BUN), creatinine) and adverse events
(signs and symptoms) were recorded before the study
as well as at 3 months and 6 months.
Statistical analyses
Analyses were undertaken with SPSS v15.0 (IBM, Ar-
monk, NY, USA). Qualitative data were assessed by the
chi-square test, Fisher's exact test or Wilcoxon rank
sum test between two groups. The Student's t-test was
used if quantitative data had a normal distribution,
and the Wilcoxon rank sum test if not. Single-factor re-
peated-measures analysis of variance (Mauchly's test of
sphericity) was used for comparisons before and after
treatment within treatment and control groups. All sta-
tistical tests and confidence intervals were two-sided.
P ≤ 0.05 was considered significant, and P ≤ 0.01 high-
ly significant.
RESULTS
Baseline characteristics
During the study period, 20 (20% ) of 100 patients
were lost to follow-up, and three (3%) were excluded.
There were 62 patients in the treatment group, and 15
in the control group (Figure 1).
There were no significant differences (P > 0.05) in sex
(χ2 = 4.000, P = 0.261), height (P = 0.364), weight
(P = 0.455), systolic blood pressure (P = 0.092), dia-
stolic pressure (P = 0.644), or history of smoking (χ2 =
0.542, P = 0.770) between the two groups (Table 1).
MRCDS scores
There was a significant difference between the two
groups at baseline (P = 0.000). Then, we compared the
change between each follow-up visit. There were no sig-
nificant differences in MRCDS scores from baseline to
3 months between the two groups (P = 0.111), where-
as those from baseline to 6 months (P = 0.001) and
from 3 months to 6 months (P = 0.009) were signifi-
cant. Improvement in MRCDS scores in the treatment
group tended to be better after a prolonged period of
therapy (Table 2).
Comparison of MRCDS scores from before to after
treatment in each group showed that the difference was
significant in the FG group (P = 0.000) but not in the
JC group (P = 0.254). Taking FGs tended to improve
MRCDS scores (Table 3).
SGHRQ scores
Assessed to eligibility (n = 100)
Randomized
(n = 100)
Base line Treatment group(n = 80) Control group (n = 20)
Follow-up at 3 months Analyzed (n = 62)18 were lost to
follow-up
Analyzed (n = 15)
5 were lost to follow-up
Follow-up at 6 months Analyzed (n = 62) Analyzed (n = 15)
Figure 1 Flow chart of the study
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There was a significant difference between the two
groups at baseline (P < 0.05). Differences in respirato-
ry symptoms were significant between each follow-up
visit (P < 0.05). There was no significant difference in
activity limitation between each follow-up visit (P >
0.05). Disease effects showed no significant difference
from 3 months to 6 months (P = 0.614) but a signifi-
cant difference was observed from baseline to 6
months and from baseline to 3 months (P < 0.05). To-
tal score of the SGHRQ from baseline to 3 months
showed a significant difference (P = 0.011 446). Im-
provements in respiratory symptoms and disease effects
were more significant in the treatment group after a
prolonged duration of therapy (Table 4).
Comparison of SGHRQ scores from before to after
treatment in each group showed a significant difference
in the FG group (P < 0.05), but not in the JC group
(P > 0.05). Taking FGs tended to improve MRCDS
scores (Table 5).
Lung function
Differences in lung function (VC, FEV1/FVC, FEV1%,
TLC, DLCO, DLCO/Va) between each follow-up visit
were not significant (P > 0.05). Differences in FVC be-
tween the two groups were significant at baseline (P =
0.0080). There was no significant difference in FVC
between each follow-up visit (P > 0.05).
Comparison of lung function from before to after treat-
ment in each group showed that only the difference in
DLCO/Va was significant in the FG group (P =
0.003), whereas there was no significant difference in
the JC group (P > 0.05). Taking FGs tended to im-
prove DLCO/Va.
TCMSS
The difference between the two groups was significant
at baseline (P < 0.05). Then, we compared the change
between each follow-up visit. The difference in the to-
tal TCMSS in the treatment group between each fol-
low-up visit was significant (P < 0.05). Improvement
in the TCMSS was better in the treatment group (Ta-
Table 1 Characteristics of the patients at baseline ( xˉ ± s)
Group
Treatment
Control
n
62
15
Gender
(Male/Female)
64.56
56.67
Height
(cm)
166±8
167±7
Weight
(kg)
67±10
70±13
SBP
(mm Hg)
126±14
118±15
DBP
(mm Hg)
76±8
75±7
History of smoking
(Y/N)
26/36
5/10
Notes: treatment group were treated with Feiwei granules (two bags per time, twice a day); control group were treated with Jinshuibao cap-
sules (three capsules per time, three times a day). SBP: systolic blood pressure; DBP: diastolic blood pressure.
Table 2 Comparison of the change in dyspnea scores between different follow-up visits ( xˉ ± s)
Group
Treatment
Control
n
62
15
Baseline-Months 3
－0.6±0.7a
－0.3±0.7
Baseline-Months 6
－0.8±0.8b
0.1±1.0
Months 3-Months 6
－0.2±0.7b
0.3±0.7
Notes: treatment group were treated with Feiwei granules (two bags per time, twice a day); control group were treated with Jinshuibao cap-
sules (three capsules per time, three times a day). aP > 0.05, bP < 0.05, compared with control group.
Group
Treatment
Control
n
62
15
Baseline
2.4±0.8
1.4±0.8
Months 3
1.8±0.9
1.1±0.8
Months 6
1.6±0.9
1.5±1.2
Mauchly's test of sphericity
0.064
0.270
F value
37.434
1.441
P value
0.000
0.254
Notes: treatment group were treated with Feiwei granules (two bags per time, twice a day); control group were treated with Jinshuibao cap-
sules (three capsules per time, three times a day).
Table 3 Comparison of dyspnea scores from before to after treatment in each group ( xˉ ± s)
Table 4 Comparison of the change in SGRQ scores between different follow-up visits ( xˉ ± s)
Item
Respiratory symptoms
Activity limitation
Disease affect
SGRQ total scores
Group
Treatment
Control
Treatment
Control
Treatment
Control
Treatment
Control
n
62
15
62
15
62
15
62
15
Baseline-Months 3
－5±18a
2±8
－6±13b
－3±13
－11±17a
－3±9
－8±14a
－1±6
Baseline-Months 6
－9±22a
5±8
－11±18b
－2±11
－17±21a
－7±14
－14±19b
－3±10
Months 3- 6
－4±13a
4±13
－5±13b
1±10
－5±12b
－4±15
－6±10b
－2±10
Notes: treatment group were treated with Feiwei granules (two bags per time, twice a day); control group were treated with Jinshuibao cap-
sules (three capsules per time, three times a day). aP > 0.05, bP < 0.05, compared with control group.
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ble 6).
Comparison of the TCMSS from before to after treat-
ment in each group showed that the difference was sig-
nificant in the FG group (P = 0.000), whereas there
was no significant difference in the JC group (P =
0.444). Taking FGs tended to improve the TCMSS
(Table 7).
6MWT
Comparison of the 6MWT between the two groups
showed that there was no significant difference be-
tween each follow-up visit (P > 0.05). Improvement in
the TCMSS was better in the FG group from baseline
to 6 months and from 3 months to 6 months (Table 8).
Comparison of the 6-min walking test from before to
after treatment in each group showed that differences
were significant in the treatment group and control
group (P < 0.05). The FG group showed a significant
difference (P = 0.000), but the JC group did not (P =
0.444). Taking FGs and JCs tended to improve the
6MWT (Table 9).
Blood gas analyses
There were no significant differences in blood gas anal-
yses (pH, PO2, PCO2, HCO3) between the two groups
(P > 0.05).
Comparison of blood gas analyses from before to after
treatment in each group showed that only the differ-
ence in PO2 was significant in the FG group (P =
0.044), whereas there were no significant differences in
the JC group (P > 0.05). Taking FGs tended to im-
prove PO2.
Safety assessment
There were no significant differences in blood and
urine tests, or levels of ALT, BUN, or creatinine be-
tween the two groups (P > 0.05), or from before to af-
ter treatment in the FG group (P > 0.05).
Abnormal ECGs were not observed in the JC group at
baseline. However, three cases of bradycardia, one of
tachycardia, one of occasional premature ventricular
contraction, and one of ST-T wave change in the FG
group were noted. During treatment, there were no
changes in either group.
DISCUSSION
Guidelines set by the ATS/ERS/JRS/ALAT in 2011
stated that there were no effective therapeutic options
for IPF except lung transplantation. The recommenda-
tion for corticosteroids in patients with acute exacerba-
tions of IPF is weak.10 Long-term use of corticosteroids
can result in hypo-immunity and damage to the liver,
Table 5 Comparison of SGHRQ scores from before to after treatment in each group ( xˉ ± s)
Item
Respiratory symptoms
Activity limitation
Disease affect
SGRQ total scores
Group
Treatment
Control
Treatment
Control
Treatment
Control
Treatment
Group
n
62
15
62
15
62
15
62
15
Baseline
55±26
27±19
54±26
37±29
50±28
30±24
54±22
36±20
Months 3
50±25
28±20
49±26
34±28
38±25
27±26
46±22
35±22
Months 6
45±25
32±25
43±26
35±28
33±24
23±20
41±23
33±20
Mauchly's test
of sphericity
0.000
0.009
0.000
0.618
0.000
0.117
0.000
0.127
F value
8.361
2.126
17.111
0.519
32.735
2.103
25.373
1.043
P value
0.001
0.158
0.000
0.601
0.000
0.141
0.000
0.366
Notes: treatment group were treated with Feiwei granules (two bags per time, twice a day); control group were treated with Jinshuibao cap-
sules (three capsules per time, three times a day). SGHRQ: soant george's hospital respiratory queationaire.
Table 6 Comparison of TCM syndrome scores between different follow-up visits ( xˉ ± s)
Group
Treatment
Control
n
62
15
Baseline-Months 3
－6±7a
－2±6
Baseline-Months 6
－11±9a
－2±9
Months 3-6
－5±6a
－1±6
Notes: treatment group were treated with Feiwei granules (two bags per time, twice a day); control group were treated with Jinshuibao cap-
sules (three capsules per time, three times a day). aP > 0.05, compared with control group. TCM: Traditional Chinese Medicine.
Group
Treatment
Control
n
62
15
Baseline
28±8
22±7
Months 3
21±7
20±7
Months 6
17±8
20±9
Mauchly's Test of Sphericity
0.001
0.029
F value
71.430
0.742
P value
0.000
0.444
Notes: treatment group were treated with Feiwei granules (two bags per time, twice a day); control group were treated with Jinshuibao cap-
sules (three capsules per time, three times a day). TCM: Traditional Chinese Medicine.
Table 7 Comparison of TCM syndrome scores from before to after treatment in each group ( xˉ ± s)
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kidneys and other organs, can trigger new infections,
and can even increase the risk of respiratory failure.11
Lung transplantation is restricted by donor sources and
expense. Therefore, research has focused on treating
IPF with more effective and safe pharmaceutical drugs,
some of which are TCMs.
The main component of JCs is powdered Cordyceps
fungus, which benefits the lungs and kidneys by secur-
ing essence and tonifying Qi. It can be used in the
TCM syndromes of lung-kidney deficiency, absence of
essence Qi, chronic cough with asthma, fatigue, sleep-
lessness and forgetfulness, weakness in the waist and
knees, irregular menstruation, impotence, and prema-
ture ejaculation.
Several studies have shown that the main active ingredi-
ents of Cordyceps sinensis are D-mannitol and polysac-
charide, as well as other amino acids, nucleotides, sugar
alcohols, sterols, peptides, vitamins, inorganic elements
and polyamines that are essential for humans. Those
compounds can regulate immune function, anti-oxida-
tion actions, and anti-tumor actions, inhibit the inflam-
matory response, regulate blood lipids, promote tissue
repair, adjust immune functions, relax bronchial
smooth muscle, regulate metabolism, and resist pulmo-
nary fibrosis.12-14 Xu et al 15 demonstrated that Cordy-
ceps sinensis liquid can improve the early alveolitis
seen in pulmonary fibrosis. Yang et al 16 found that
Cordyceps mycelia powder can inhibit excess deposi-
tion of collagen fibers.Yang et al 17 treated rats with pul-
monary fibrosis with Cordyceps mycelia powder, and
found that it could improve gas exchange, relieve infil-
tration of inflammatory cells, and suppress and prevent
pulmonary fibrosis. JCs are used widely to treat IPF.
In the present study, after consulting experts in respira-
tory disease, we used JCs combined with prednisone as
the control group. We found that the efficacy of FGs
was similar to that of JCs. FGs improved various indi-
ces after administration and were superior to JCs in
some indices. Serious treatment-related adverse events
were not observed.
The present study had limitations. First, we used pred-
nisone as a basic treatment according to the guidelines
on the diagnosis and treatment of IPF set by the Chi-
nese Thoracic Society in 2002. However, in the latest
international guideline, prednisone is no longer the rec-
ommendation for basic treatment. Second, the observa-
tion period was 6 months, whereas the observation pe-
riod of large international IPF studies is often 48-52
weeks.18
In conclusion, FGs improved dyspnea scores, SGHRQ
scores, DLCO/Va, total TCMSS, and 6-min walking
test in IPF patients whose TCM syndrome was lung–
kidney deficiency and Qi deficiency with blood stasis.
FGs were similar to JCs for IPF treatment. This study
indicates that FGs was safe in treating IPF patients. It
is beneficial to the treatment based on syndrome differ-
entiation for physicians and convenient for patients.
Further study is needed to confirm our pilot findings.
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